The late-stage TOURMALINE-MM2 trial featured 705 adult patients who are newly diagnosed with multiple myeloma and are not candidates for transplant. NINLARO is an oral proteasome inhibitor, which
INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. InMed has conducted preclinical pharmacology studies that suggest
Planned to be branded as EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, KPI-121 showed statistically significant results for primary and also key secondary endpoints in comparison to placebo in
MAVIRET was already indicated as an 8-week, pan-genotypic (GT1-6), once-daily regimen for treatment-naïve HCV patients without cirrhosis, and as an 8-week, once-daily regimen for treatment-naïve GT 1, 2,
BCX9930 is an oral Factor D inhibitor discovered and developed by BioCryst for the treatment of complement-mediated diseases. The company expects to report data from the proof of
Boston-based Omega Funds led the financing, with participation from existing investor Frazier Healthcare Partners and new investors Longitude Capital, Redmile Group, Polaris Partners, Casdin Capital, Two River, Venrock,
As part of the collaboration, the AI-driven generative modelling technology of Iktos will be combined with SynFini, a fully automated end-to-end synthetic chemistry system developed by SRI. The
The Series B financing was led by Pivotal bioVenture Partners, with participation from new investors Cormorant Asset Management, Cowen Healthcare Investments, EcoR1 Capital, Fidelity Management & Research Company,
According to the company, Advil Dual Action with Acetaminophen is now the first OTC combination of ibuprofen and acetaminophen to get approval in the US. The new product
Financial considerations Under the terms of the agreement, AstraZeneca has received a payment of $350m from Atnahs. The Company may also receive future sales-contingent payments of up to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.